KR101789430B1 - Smo 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 조성물 - Google Patents

Smo 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 조성물 Download PDF

Info

Publication number
KR101789430B1
KR101789430B1 KR1020160081189A KR20160081189A KR101789430B1 KR 101789430 B1 KR101789430 B1 KR 101789430B1 KR 1020160081189 A KR1020160081189 A KR 1020160081189A KR 20160081189 A KR20160081189 A KR 20160081189A KR 101789430 B1 KR101789430 B1 KR 101789430B1
Authority
KR
South Korea
Prior art keywords
cancer
quinazolin
pyridin
compound
dimethylmorpholino
Prior art date
Application number
KR1020160081189A
Other languages
English (en)
Korean (ko)
Inventor
이경
고혁완
바타라이 디팍
김민경
정주현
이한규
Original Assignee
동국대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 동국대학교 산학협력단 filed Critical 동국대학교 산학협력단
Priority to KR1020160081189A priority Critical patent/KR101789430B1/ko
Priority to PCT/KR2017/006692 priority patent/WO2018004213A1/fr
Application granted granted Critical
Publication of KR101789430B1 publication Critical patent/KR101789430B1/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020160081189A 2016-06-28 2016-06-28 Smo 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 조성물 KR101789430B1 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020160081189A KR101789430B1 (ko) 2016-06-28 2016-06-28 Smo 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 조성물
PCT/KR2017/006692 WO2018004213A1 (fr) 2016-06-28 2017-06-26 Nouveau composé ayant une activité inhibitrice de smo et composition comprenant celui-ci en tant qu'ingrédient actif pour prévenir ou traiter le cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020160081189A KR101789430B1 (ko) 2016-06-28 2016-06-28 Smo 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
KR101789430B1 true KR101789430B1 (ko) 2017-10-25

Family

ID=60299871

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020160081189A KR101789430B1 (ko) 2016-06-28 2016-06-28 Smo 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 조성물

Country Status (2)

Country Link
KR (1) KR101789430B1 (fr)
WO (1) WO2018004213A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220161875A (ko) * 2021-05-31 2022-12-07 주식회사 헤지호그 Gli 활성을 억제하는 피페리딘 유도체 화합물 및 이의 암 치료 용도

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113227089A (zh) 2018-10-31 2021-08-06 吉利德科学公司 作为hpk1抑制剂的取代的6-氮杂苯并咪唑化合物
CA3116347A1 (fr) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Composes 6-azabenzimidazole substitues ayant une activite inhibitrice de hpk1
EP3972695A1 (fr) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Exo-méthylène-oxindoles substitués qui sont des inhibiteurs de hpk1/map4k1
WO2021020363A1 (fr) 2019-07-29 2021-02-04 武田薬品工業株式会社 Composé hétérocyclique
CN114957219B (zh) * 2022-05-10 2023-12-15 苏州大学 一种靶向降解Gli1蛋白的降解剂及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019800A2 (fr) 1999-09-16 2001-03-22 Curis, Inc. Mediateurs de voies de signalisation hedgehog, preparations et utilisations associees
WO2005021532A1 (fr) 2003-08-25 2005-03-10 Amgen Inc Derives 2,3-dihydro-1h-isoindol-1-one substitues et techniques d'utilisation
WO2005123696A1 (fr) 2004-06-15 2005-12-29 Astrazeneca Ab Quinazolones substitues en tant qu'agents anticancereux
WO2010084050A2 (fr) 2009-01-13 2010-07-29 Novartis Ag Dérivés de quinazolinone utiles comme antagonistes vanilloïdes
WO2012016876A1 (fr) 2010-08-03 2012-02-09 Nerviano Medical Sciences S.R.L. Combinaison thérapeutique comprenant un inhibiteur de parp-1 et un agent antinéoplasique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07258224A (ja) * 1994-03-24 1995-10-09 Dai Ichi Seiyaku Co Ltd 二環性化合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019800A2 (fr) 1999-09-16 2001-03-22 Curis, Inc. Mediateurs de voies de signalisation hedgehog, preparations et utilisations associees
WO2005021532A1 (fr) 2003-08-25 2005-03-10 Amgen Inc Derives 2,3-dihydro-1h-isoindol-1-one substitues et techniques d'utilisation
WO2005123696A1 (fr) 2004-06-15 2005-12-29 Astrazeneca Ab Quinazolones substitues en tant qu'agents anticancereux
WO2010084050A2 (fr) 2009-01-13 2010-07-29 Novartis Ag Dérivés de quinazolinone utiles comme antagonistes vanilloïdes
WO2012016876A1 (fr) 2010-08-03 2012-02-09 Nerviano Medical Sciences S.R.L. Combinaison thérapeutique comprenant un inhibiteur de parp-1 et un agent antinéoplasique

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220161875A (ko) * 2021-05-31 2022-12-07 주식회사 헤지호그 Gli 활성을 억제하는 피페리딘 유도체 화합물 및 이의 암 치료 용도
KR102553669B1 (ko) 2021-05-31 2023-07-11 주식회사 헤지호그 Gli 활성을 억제하는 피페리딘 유도체 화합물 및 이의 암 치료 용도

Also Published As

Publication number Publication date
WO2018004213A1 (fr) 2018-01-04

Similar Documents

Publication Publication Date Title
KR101789430B1 (ko) Smo 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 조성물
JP5452811B2 (ja) 有糸分裂進行を阻害するための化合物
CN105611933B (zh) 抗增生性化合物
CN103261198A (zh) 2-芳基咪唑并[1, 2-b]哒嗪、2-苯基咪唑并[1, 2-a]吡啶、和2-苯基咪唑并[1, 2-a]吡嗪衍生物
MXPA04010441A (es) Derivado de pirazolo[1,5-a]pirimidina e inhibidor de nad(p)h oxidasa que contiene el mismo.
EA024194B1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
EP2581371B1 (fr) Dérivés de dihydro-indol-2-one substitués par un groupe pyrrolyle, procédés pour les préparer et leurs utilisations
JP7323896B2 (ja) カゼインキナーゼ１ε阻害剤、医薬組成物及びその使用
JP2019524790A (ja) チエノピリミジン系化合物、その製造方法、医薬組成物およびその応用
KR20210038906A (ko) 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
KR20200054096A (ko) Yap-tead 결합을 저해하는 화합물 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약제학적 조성물
CN103214481B (zh) 新型咪唑并[1,2-a]吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
CN107383016A (zh) 含杂芳基酰胺结构的吡咯并嘧啶化合物的制备及应用
CN109988151B (zh) 一种炔类化合物、制备方法及其应用
KR20190114299A (ko) RhoA 억제제 및 이의 용도
CN105272995B (zh) 喹啉类衍生物、其药物组合物、制备方法及应用
CN106810549A (zh) 含有二氢哒嗪结构的7‑氮杂吲哚类化合物及其应用
CN110407839B (zh) 含杂芳基酰胺结构的三唑并杂环类化合物的制备及应用
CN111662228B (zh) 吡啶酮酰联芳基胺类化合物及其用途
JP2021073292A (ja) ピリジン系化合物を有効成分として含有するｄｙｒｋ関連疾患の予防又は治療用薬学的組成物
KR101948555B1 (ko) 수용체 티로신 키나아제 저해제를 유효성분으로 함유하는 암 예방 또는 치료용 약학조성물
KR102548888B1 (ko) 신규한 트리사이클릭 유도체 화합물 및 이의 용도
KR101697062B1 (ko) 물에 대한 용해도가 개선된 신규 제라닐 프라보노이드 유도체, 이의 제조 방법 및 이를 유효성분으로 포함하는 암 예방 및 치료용 약학적 조성물
KR20190114300A (ko) RhoA 억제제 및 이의 용도
WO2015144029A1 (fr) Dérivé de la méthacryloyl-benzimidazolone et son utilisation comme agent anti-tumoral

Legal Events

Date Code Title Description
E701 Decision to grant or registration of patent right
GRNT Written decision to grant